Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.4936
-0.0123 (-2.43%)
Nov 17, 2026, 9:41 AM EST - Market open
Coherus Oncology Revenue
Coherus Oncology had revenue of $14.27M in the quarter ending September 30, 2026, with 23.36% growth. This brings the company's total for the last twelve months to $53.64M. In the year 2025, Coherus Oncology had annual revenue of $42.17M with 59.81% growth. That makes Coherus Oncology the 27,501st largest company in the world by revenue and 3,726th in the United States.
Revenue (ttm)
$53.64M
Revenue Growth
+59.81%
P/S Ratio
1.46
Revenue / Employee
$369,924
Employees
145
Market Cap
76.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.17M | 15.78M | 59.81% |
| Dec 31, 2024 | 26.39M | -230.86M | -89.74% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 32.10M |
| Seer, Inc. | 14.08M |
| Rani Therapeutics Holdings | 6.58M |
| Kazia Therapeutics | 1.27M |
| Rallybio | 434.00K |
CHRS News
- 1 day ago - Coherus Oncology Transcript: Jefferies Global Healthcare Conference - Transcripts
- 5 days ago - Oncolytics enters clinical supply agreement with Coherus Oncology - TheFly
- 6 days ago - Coherus Oncology Slides: Corporate presentation - Filings
- 6 days ago - Coherus Oncology reports Q3 EPS (20c), consensus (21c) - TheFly
- 6 days ago - Coherus Oncology price target lowered to $8 from $10 at Guggenheim - TheFly
- 7 days ago - Coherus Oncology Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - Coherus Oncology Earnings Call Transcript: Q3 2026 - Transcripts
- 7 days ago - Coherus Oncology Earnings release: Q3 2026 - Filings